The Europe Prostate Cancer market size stood at around USD 16.69 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Prostate cancer is the cancer occurring in the prostate gland in males, which may be asymptomatic or may present with difficulty in urination, blood in urine, loss of weight. Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall.
In Netherlands, it is the most common cancer in males, making up 26% of all cancer diagnosis in men.
In 2017, the total expenditure on prostate cancer was 385.9 million euros. This corresponds to 0.44% of the total expenditure on Dutch health care. The care for men with prostate cancer comprises 6.6% of all health care expenditure incurred for neoplasms. Nearly 85% of prostate cancer healthcare expenditure is for hospital care and specialist medical care. The other health care expenditure is mainly for medicines and aids (8%).
The market will be driven by the growing innovation and digitalisation of diagnostic and screening methods like multiparametric MRI, which will improve detection of tumours.
Another market driver will be the increased focus on research and development of new drugs like Progenics, Xofigo.
Prostate cancer has high prevalence in Netherlands. The number of cases reported in 2019 were 13,478. In 2020, the number was less (12,815) presumably due to fewer diagnosis in COVID 19. It remains, however, the most common cancer in males. With increasing awareness the prostate cancer market is expanding.